Beteiligungsmeldung
Kuros Biosciences AG
Gemeinsam gemeldeter Anteil
44.52%
Threshold
Crossed upwards
Timeline
Published
09.12.2015
Transaction
01.12.2015
Voting rights breakdown
Gemeldete wirtschaftlich Berechtigte · 5
Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.
Notice details
Meldungs-ID
TBFC800022
Beneficial owner
LSP V Coöperatieve U.A
Gemeldete Adresse
LSP V Coöperatieve U.A., 1071 DV Amsterdam
Each investor has undertaken severally, not jointly, to exchange its shares in Kuros against shares in Cytos as outlined in the combination agreement between Cytos and Kuros dated December 1, 2015, and subject to the terms and conditions set forth therein. At the closing of the transaction, Cytos is expected to issue between 353,006,886 new registered shares (assuming 90% of Kuros shares are exchanged for new Cytos shares) and 392,229,873 new registered shares (assuming 100% of Kuros shares are exchanged for new Cytos shares). Accordingly, the number of shares/voting rights pursuant to the entry in the commercial register will be between 461,022,162 and 500,245,149 at the time the investors will actually become shareholders in Cytos. It is expected that the investors will hold between 9.61% and 10.43% total equity securities and purchase positions post closing. LSP V Management BV is the sole director of LSP V Coöperatieve U.A., a multi-investor fund. LSP Management Group BV is the sole shareholder of LSP V Management BV. Messrs. Kleijwegt, Kuijten, Rothe and Wegter are shareholders of LSP Management Group BV.
insider24.ch
Verpassen Sie kein Marktsignal mehr
Mehr benötigt? Pro-Angebot entdecken